



## Second Sight to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 Conference Call

March 6, 2019

**Los Angeles, CA –March 6, 2019** - Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, will release its 2018 fourth quarter and year-end financial results on Wednesday, March 13, 2019, after the close of the U.S. financial markets.

Will McGuire, President and Chief Executive Officer, and John T. Blake, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date	Wednesday, March 13, 2019
Time	4:30 p.m. EDT
Toll free (U.S.)	<a href="tel:888-221-1887">(888) 221-1887</a>
International	<a href="tel:303-223-4366">(303) 223-4366</a>
Webcast (live and replay)	<a href="http://www.secondsight.com">www.secondsight.com</a> under the 'Investors' section.

A replay of the conference call will be available for two weeks after the call's completion by dialing [\(800\) 633-8284](tel:800-633-8284) (U.S.) or [\(402\) 977-9140](tel:402-977-9140) (International). The conference ID for the replay is 21918961. The archived webcast will be available for 30 days via the aforementioned URL.

### About Second Sight

Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals.

Second Sight's Argus<sup>®</sup> II Retinal Prosthesis System is the only FDA and CE Mark approved device for treating retinitis pigmentosa, with proven implant durability of multiple years. In 2016, the Company published five year results. Today, several Argus II devices have been implanted and continue to be operational in humans for more than 10 years. The Company is developing the Orion<sup>®</sup> Visual Cortical Prosthesis which is intended to provide useful artificial vision to individuals who are blind due to various causes. The Company's U.S. headquarters are in Los Angeles, California and European headquarters are in Lausanne, Switzerland. More information is available at [www.secondsight.com](http://www.secondsight.com).

### Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," "goal," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or

that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on March 20, 2018 and Form 10-Q, filed on November 8, 2018, and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

**Investor Relations Contacts:**

Institutional Investors

In-Site Communications, Inc.

Lisa Wilson, President

T: [212-452-2793](tel:212-452-2793)

E: [lwilson@insitecony.com](mailto:lwilson@insitecony.com)

or

Individual Investors

MZ North America

Greg Falesnik, Managing Director

T: [949-385-6449](tel:949-385-6449)

E: [greg.falesnik@mzgroup.us](mailto:greg.falesnik@mzgroup.us)

Media Contacts:

Nobles Global Communications

Laura Nobles or Helen Shik

T: [617-510-4373](tel:617-510-4373)

E: [Laura@noblesgc.com](mailto:Laura@noblesgc.com)

E: [Helen@noblesgc.com](mailto:Helen@noblesgc.com)